Trial Profile

Phase I Multicenter, Open-label, Clinical and Pharmacokinetic Study of Lurbinectedin (PM01183) in Combination With Weekly Paclitaxel, With or Without Bevacizumab, in Patients With Selected Advanced Solid Tumors

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 18 Aug 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Lurbinectedin (Primary) ; Paclitaxel (Primary) ; Bevacizumab
Indications Adenocarcinoma; Advanced breast cancer; Carcinoma; Endometrial cancer; Germ cell and embryonal neoplasms; Germ cell cancer; Gynaecological cancer; Head and neck cancer; Non-small cell lung cancer; Ovarian cancer; Small cell lung cancer; Solid tumours; Squamous cell cancer
Focus Adverse reactions
Sponsors PharmaMar

10 Aug 2022 Results published in the Investigational New Drugs
19 Sep 2019 Results published in the Luye Pharma Group Media Release.
19 Sep 2019 According to an Luye Pharma Group media release, clinical data from this study were presented at the World Conference on Lung Cancer.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com